Loading
NASDAQHealthcareMedical - Devices
Latest quote
$9.04
+$0.32 · +3.67%
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Previous close
$9.04
+$0.32 · +3.67%
Regular session · ET · Market data may be delayed.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Day range
Current $9.04
52-week range
Current $9.04
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
26
Expensive
Sentiment
60
Mixed
Risk
42
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Day range
Current $9.04
52-week range
Current $9.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.91M USD | 2.7M USD | 2.73M USD | 3.2M USD | 5.83M USD |
| Cost of goods sold | 2.23M USD | 1.44M USD | 1.86M USD | 2.9M USD | 3.93M USD |
| Gross profit | −317K USD | 1.27M USD | 876.8K USD | 298.38K USD | 1.91M USD |
| Research and development | 69.12M USD | 51.45M USD | 31.02M USD | 17.59M USD | 9.99M USD |
| Selling, general, and administrative | 24.46M USD | — | 17.05M USD | 15.21M USD | 9.14M USD |
| Operating expenses | 93.58M USD | 79.64M USD | 49.02M USD | 31.41M USD | 18.77M USD |
| Interest income | 709K USD | — | 428.06K USD | 210.38K USD | 68.55K USD |
| Interest expense | 73K USD | 82K USD | 67.09K USD | 648.71K USD | 1.03M USD |
| Depreciation and amortization | 1.66M USD | 1.51M USD | 1.16M USD | 774.08K USD | 640.09K USD |
| Operating income | −93.89M USD | −78.37M USD | −48.14M USD | −31.11M USD | −16.86M USD |
| Net income | −94.14M USD | −76.29M USD | −46.02M USD | −30.56M USD | −17.17M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.00
99.12% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM17.79M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF6.91M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN6.45M0.05%14.47B USD0.24%$224.62+0.40%
Vanguard Russell 2000 ETFVTWO3.59M0.02%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC2.35M0.16%1.47B USD0.60%$196.25+0.69%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS1.6M0.38%417.95M USD0.60%$110.27+1.10%
Fidelity Enhanced Small Cap ETFFESM1.29M0.02%6.03B USD0.28%$47.36+0.21%
State Street SPDR S&P Health Care Equipment ETFXHE1.06M0.59%179.1M USD0.35%$94.16-0.13%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco Dorsey Wright SmallCap Momentum ETFDWASFidelity Enhanced Small Cap ETFFESMState Street SPDR S&P Health Care Equipment ETFXHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
